Revolution Medicines, Inc.

This study tests a new combination of drugs (RAS(ON) inhibitors plus ivonescimab) in adults with advanced or metastatic solid tumors that have a RAS mutation. The goal is to see if the combination is safe and can shrink tumors or slow their growth. About 370 people with cancers l…

This study is testing several new experimental drugs (RAS(ON) inhibitors) combined with standard chemotherapy or other targeted therapies for people with advanced colorectal or pancreatic cancer. The goal is to see if these combinations are safe and can shrink tumors. About 1,130…

This study tests a new drug called daraxonrasib to see if it can delay or prevent pancreatic cancer from returning after surgery and chemotherapy. About 500 adults who have had their pancreatic cancer removed will be randomly assigned to receive the drug or just be watched. The g…

This study tests two experimental drugs, elironrasib and daraxonrasib, given alone or together, in people with advanced solid tumors that have a specific KRAS G12C mutation. The goal is to see if the drugs are safe and can shrink or control tumors. About 534 adults with lung, col…

This early-stage study tests a new drug called RMC-5127 in adults with advanced solid tumors that have a specific KRAS G12V gene change. The main goals are to check safety, find the right dose, and see if the drug can shrink tumors. About 574 people with lung, colorectal, or panc…

This study is testing new drugs called RAS(ON) inhibitors in people with advanced non-small cell lung cancer that has a RAS mutation. The goal is to see if these drugs are safe and can shrink tumors or slow the cancer's growth. About 616 adults will receive the drugs alone or wit…

This study tests a new drug called daraxonrasib, either alone or with standard chemotherapy, for people with metastatic pancreatic cancer that has spread. About 900 adults with a RAS gene mutation will be randomly assigned to one of three treatment groups. The goal is to see if t…

This study tests a new oral drug, RMC-6236, against standard chemotherapy (docetaxel) in people with advanced non-small cell lung cancer that has a specific RAS mutation and has already been treated with immunotherapy and platinum chemo. About 420 adults will be randomly assigned…

This study tests an experimental drug called RMC-6236 in about 754 adults with advanced solid tumors that have specific RAS gene mutations, including certain lung, colorectal, and pancreatic cancers. The main goals are to check the drug's safety and find the right dose. Participa…